HRS/EHRA expert consensus statement recommended that DCM patients with significant cardiac conduction disorder and/or a family history of premature unexpected SCD should undergo comprehensive or targeted (LMNA and SCN5A) genetic testing (31). This evidence concerns the gene SCN5A and familial dilated cardiomyopathy.